From detection to drug delivery: innovations in cancer biosensors from concept to clinical impact

Cancer continues to pose a significant global health burden, driving the demand for more precise diagnostic and therapeutic approaches. This review highlights the rapid evolution of biosensor technologies and their expanding role in oncology starting from early cancer detection to advanced drug delivery systems. Traditional treatments, while foundational, often suffer from limitations such as non-specific toxicity and therapeutic resistance. In contrast, biosensors offer high sensitivity, specificity, and real-time detection capabilities, enabling accurate monitoring of cancer biomarkers. For example, electrochemical biosensors based on aptamer-functionalized nanomaterials have demonstrated femtomolar detection limits for biomarkers like carcinoembryonic antigen (CEA) and HER2/neu. Emerging wearable biosensors and AI-integrated point-of-care systems now enable continuous monitoring of circulating miRNAs, ctDNA, and exosomes in patient biofluids. We present an in-depth analysis of various biosensor platforms, including electrochemical, optical, microfluidic, nanomaterial-enhanced, and metal–organic framework (MOF)-based systems. Particular focus is given to label-free and nucleic acid-based biosensors designed for microRNA (miRNA) detection, which are proving critical in early-stage cancer diagnostics. Quantitative performance metrics such as sensitivity (> 90%), specificity, and detection thresholds (as low as 8 fg/mL in clinical samples) are discussed for key biosensor models. Additionally, we explore the integration of biosensors into smart drug delivery systems, emphasizing nanotechnology's role in improving targeted therapeutic outcomes. The review concludes with insights into emerging directions such as liquid biopsy techniques, artificial intelligence-assisted diagnostics, and precision medicine. Collectively, these innovations position biosensors as essential tools in the future landscape of personalized and efficient cancer care.

Institutions

Publication Details

Journal
Biotechnology for Sustainable Materials
Published
2025-10-01
DOI
https://doi.org/10.1186/s44316-025-00040-3
Citations
1
Primary Topic
Genomics and Phylogenetic Studies
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From detection to drug delivery: innovations in cancer biosensors from concept to clinical impact

1 citations
Biotechnology for Sustainable Materials
Genomics and Phylogenetic Studies
0.81
article

From detection to drug delivery: innovations in cancer biosensors from concept to clinical impact

article en
1 citations

Abstract

Cancer continues to pose a significant global health burden, driving the demand for more precise diagnostic and therapeutic approaches. This review highlights the rapid evolution of biosensor technologies and their expanding role in oncology starting from early cancer detection to advanced drug delivery systems. Traditional treatments, while foundational, often suffer from limitations such as non-specific toxicity and therapeutic resistance. In contrast, biosensors offer high sensitivity, specificity, and real-time detection capabilities, enabling accurate monitoring of cancer biomarkers. For example, electrochemical biosensors based on aptamer-functionalized nanomaterials have demonstrated femtomolar detection limits for biomarkers like carcinoembryonic antigen (CEA) and HER2/neu. Emerging wearable biosensors and AI-integrated point-of-care systems now enable continuous monitoring of circulating miRNAs, ctDNA, and exosomes in patient biofluids. We present an in-depth analysis of various biosensor platforms, including electrochemical, optical, microfluidic, nanomaterial-enhanced, and metal–organic framework (MOF)-based systems. Particular focus is given to label-free and nucleic acid-based biosensors designed for microRNA (miRNA) detection, which are proving critical in early-stage cancer diagnostics. Quantitative performance metrics such as sensitivity (> 90%), specificity, and detection thresholds (as low as 8 fg/mL in clinical samples) are discussed for key biosensor models. Additionally, we explore the integration of biosensors into smart drug delivery systems, emphasizing nanotechnology's role in improving targeted therapeutic outcomes. The review concludes with insights into emerging directions such as liquid biopsy techniques, artificial intelligence-assisted diagnostics, and precision medicine. Collectively, these innovations position biosensors as essential tools in the future landscape of personalized and efficient cancer care.

Biotechnology for Sustainable MaterialsVol. 2(1)
University of Miami (US), Banaras Hindu University (IN)
Openalex Percentile: Top 20%
Genomics and Phylogenetic Studies
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

From detection to drug delivery: innovations in cancer biosensors from concept to clinical impact · Biotechnology for Sustainable Materials (2025) | TGRS Research Map | TGRS